呋喹替尼对比安慰剂治疗难治性转移性结直肠癌(FRESCO-2):一项国际多中心随机双盲3期研究
FRESCO-2是一项在14个国家124家医院和癌症中心开展的国际多中心、随机、双盲、安慰剂对照3期研究,纳入691例既往接受过全部现行标准细胞毒及靶向治疗、且对三氟胸苷-替吡嘧啶或瑞戈非尼或两者均进展或不耐受的转移性结直肠腺癌患者,按2:1随机接受呋喹替尼5 mg胶囊口服每日一次(每28天周期第1-21天)或匹配安慰剂,均联合最佳支持治疗。中位总生存期为呋喹替尼组7.4个月(95%CI 6.7-8.2)vs 安慰剂组4.8个月(95%CI 4.0-5.8),风险比0.66(95%CI 0.55-0.80;p<0.0001)。呋喹替尼组≥3级不良事件发生率为63%,安慰剂组为50%。作者认为这些数据支持呋喹替尼作为难治性转移性结直肠癌患者的全球治疗选择。
要点
- 691例难治性转移性结直肠癌患者随机2:1接受呋喹替尼(n=461)或安慰剂(n=230),中位总生存期7.4个月 vs 4.8个月,HR 0.66(95%CI 0.55-0.80),p<0.0001。
- 入组人群既往接受转移性疾病系统治疗中位4线(IQR 3-6),502/691例(73%)接受超过3线治疗。
- 呋喹替尼组≥3级不良事件发生率63%(286/456),安慰剂组50%(116/230);呋喹替尼组最常见≥3级不良事件为高血压14%(62例)、乏力8%(35例)、手足综合征6%(29例)。
- 两组各发生1例治疗相关死亡:呋喹替尼组为肠穿孔,安慰剂组为心脏骤停。
- 呋喹替尼用法为5 mg胶囊口服每日一次,每28天周期第1-21天给药,联合最佳支持治疗。
适用人群与场景
- 年龄18岁及以上(日本为20岁及以上)、组织学或细胞学证实的转移性结直肠腺癌患者。
- 已接受所有现行标准获批的细胞毒和靶向治疗,且对三氟胸苷-替吡嘧啶或瑞戈非尼或两者均进展或不耐受。
处置流程与药物剂量
- 呋喹替尼5 mg胶囊口服,每日一次,每28天周期第1-21天给药,联合最佳支持治疗。
- 按既往三氟胸苷-替吡嘧啶或瑞戈非尼或两者、RAS突变状态、转移性疾病病程进行分层。
研究设计与关键结果
- 国际多中心、随机、双盲、安慰剂对照3期研究,在14个国家124家医院和癌症中心开展,共纳入691例患者,随机2:1接受呋喹替尼(n=461)或安慰剂(n=230)。
- 中位总生存期:呋喹替尼组7.4个月(95%CI 6.7-8.2)vs 安慰剂组4.8个月(95%CI 4.0-5.8),HR 0.66(95%CI 0.55-0.80),p<0.0001。
- ≥3级不良事件:呋喹替尼组286/456例(63%)vs 安慰剂组116/230例(50%);呋喹替尼组最常见≥3级不良事件为高血压62例(14%)、乏力35例(8%)、手足综合征29例(6%)。
- 治疗相关死亡:呋喹替尼组1例(肠穿孔),安慰剂组1例(心脏骤停)。
- 患者既往接受转移性疾病系统治疗中位4线(IQR 3-6),502/691例(73%)接受超过3线治疗。
证据类型、等级与局限
- 证据类型:国际多中心、随机、双盲、安慰剂对照3期研究(FRESCO-2)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,呋喹替尼治疗在难治性转移性结直肠癌患者中较安慰剂带来显著且具有临床意义的总生存期获益。
- 作者认为,这些数据支持呋喹替尼作为难治性转移性结直肠癌患者的全球治疗选择。
- 作者指出,正在进行的生存质量数据分析将进一步确定呋喹替尼在该人群中的临床获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: There is a paucity of effective systemic therapy options for patients with advanced, chemotherapy-refractory colorectal cancer. We aimed to evaluate the efficacy and safety of fruquintinib, a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3, in patients with heavily pretreated metastatic colorectal cancer.
METHODS: We conducted an international, randomised, double-blind, placebo-controlled, phase 3 study (FRESCO-2) at 124 hospitals and cancer centres across 14 countries. We included patients aged 18 years or older (≥20 years in Japan) with histologically or cytologically documented metastatic colorectal adenocarcinoma who had received all current standard approved cytotoxic and targeted therapies and progressed on or were intolerant to trifluridine-tipiracil or regorafenib, or both. Eligible patients were randomly assigned (2:1) to receive fruquintinib (5 mg capsule) or matched placebo orally once daily on days 1-21 in 28-day cycles, plus best supportive care. Stratification factors were previous trifluridine-tipiracil or regorafenib, or both, RAS mutation status, and duration of metastatic disease. Patients, investigators, study site personnel, and sponsors, except for selected sponsor pharmacovigilance personnel, were masked to study group assignments. The primary endpoint was overall survival, defined as the time from randomisation to death from any cause. A non-binding futility analysis was done when approximately one-third of the expected overall survival events had occurred. Final analysis occurred after 480 overall survival events. This study is registered with ClinicalTrials.gov, NCT04322539, and EudraCT, 2020-000158-88, and is ongoing but not recruiting.
FINDINGS: Between Aug 12, 2020, and Dec 2, 2021, 934 patients were assessed for eligibility and 691 were enrolled and randomly assigned to receive fruquintinib (n=461) or placebo (n=230). Patients had received a median of 4 lines (IQR 3-6) of previous systemic therapy for metastatic disease, and 502 (73%) of 691 patients had received more than 3 lines. Median overall survival was 7·4 months (95% CI 6·7-8·2) in the fruquintinib group versus 4·8 months (4·0-5·8) in the placebo group (hazard ratio 0·66, 95% CI 0·55-0·80; p<0·0001). Grade 3 or worse adverse events occurred in 286 (63%) of 456 patients who received fruquintinib and 116 (50%) of 230 who received placebo; the most common grade 3 or worse adverse events in the fruquintinib group included hypertension (n=62 [14%]), asthenia (n=35 [8%]), and hand-foot syndrome (n=29 [6%]). There was one treatment-related death in each group (intestinal perforation in the fruquintinib group and cardiac arrest in the placebo group).
INTERPRETATION: Fruquintinib treatment resulted in a significant and clinically meaningful benefit in overall survival compared with placebo in patients with refractory metastatic colorectal cancer. These data support the use of fruquintinib as a global treatment option for patients with refractory metastatic colorectal cancer. Ongoing analysis of the quality of life data will further establish the clinical benefit of fruquintinib in this patient population.
参考来源
- Dasari A, Lonardi S, Garcia-Carbonero R, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023. PMID: 37331369. doi:10.1016/S0140-6736(23)00772-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。